Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer

Loading...
Thumbnail Image
Authors
Zhu, Yahui
Zhou, Jing
Zhu, Lijing
Hu, Wenjing
Liu, Baorui
Xie, Li
Issue Date
2022-04-25
Type
Article
Language
en_US
Keywords
Cervical Cancer , Immune Therapy , Adoptive Tumor Infiltrating Lymphocytes , Potential Strategies for Improvement
Research Projects
Organizational Units
Journal Issue
Alternative Title
Abstract
Cervical cancer is one of the most common malignancies among females. As a virus-related cancer, cervical cancer has attracted a lot of attention to develop virus-targeted immune therapy, including vaccine and adoptive immune cell therapy (ACT). Adoptive tumor infiltrating lymphocytes (TILs) cell therapy has been found to be able to control advanced disease progression in some cervical cancer patients who have received several lines of treatment in a pilot clinical trial. In addition, sustainable therapeutic effect has been identified in some cases. The safety risks of TIL therapy for patients are minimal or at least manageable. In this review, we focused on the versatility of TILs and tried to summarize potential strategies to improve the therapeutic effect of TILs and discuss related perspectives.
Description
Citation
Zhu, Y., Zhou, J., Zhu, L., Hu, W., Liu, B., & Xie, L. (2022). Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer. Human vaccines & immunotherapeutics, 18(5), 2060019. https://doi.org/10.1080/21645515.2022.2060019
Publisher
Human Vaccines & Immunotherapeutics
Journal
Volume
Issue
PubMed ID
DOI
ISSN
EISSN